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Abstract
Background: Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (b-FGF), and endothelial nitric 
oxide synthase (eNOS) are factors that take part in placental angiogenesis. They are highly expressed during embryonic 
and fetal development, especially in the first trimester. In this study, we aimed to investigate the role of placental 
angiogenesis in the development of intrauterine growth restriction (IUGR) by comparing the levels of expression of 
VEGF-A, b-FGF, and eNOS in normal-term pregnancy and IUGR placentas.
Methods: The expression of VEGF-A, b-FGF, and eNOS was studied using the avidin-biotin-peroxidase method in 
placental tissues diagnosed as normal (n = 55) and IUGR (n = 55). Results were evaluated in a semi-quantitative 
manner.
Results: The expression of all the markers was significantly higher (p < 0.001) in cytotrophoblasts, syncytiotrophoblasts, 
extravillous trophoblasts, vascular smooth muscle cells, chorionic villous stromal cells, and villous vascular endothelial 
cells of the IUGR placentas when compared with those collected from normal-term pregnancies.
Conclusion: Increased expression of VEGF-A, b-FGF, and eNOS may be the result of inadequate uteroplacental 
perfusion, supporting the proposal that abnormal angiogenesis plays a role in the pathophysiology of IUGR.
Introduction
Intrauterine growth restriction (IUGR) is a complicated
placental vascular disease resulting in low birth weight,
preterm delivery, and increased perinatal morbidity and
mortality [1-4]. IUGR may be caused by various fetal,
maternal, and placental factors [1-3,5]. Angiogenesis,
defined as the development of new vascular structures, is
a placental factor playing an important role in the devel-
opment of IUGR [2-4,6,7].
Angiogenesis involves the branching of new microves-
sels from pre-existing larger blood vessels. It is an impor-
tant factor in normal embryogenesis and in physiological
processes such as ovulation and the menstrual cycle [8-
10]. Angiogenesis plays a role in the development of the
villous vasculature and the formation of terminal villi in
the human placenta. Placental vascular growth begins
early in pregnancy and continues throughout gestation
[9,11]. The villous vasculature increases in number rather
than vessel type from the 21st day of development until
the end of the first trimester. From the 26th week of ges-
tation until term, villous vascular growth changes from
branching to non-branching angiogenesis due to the for-
mation of mature intermediate villi that specialize in gas
exchange. Specific angiogenic and inhibitory factors reg-
ulate these processes [4,8,9]. IUGR occurs as a result of
the failure of elongation, branching, and dilation of the
capillary loops and of terminal villous formation [4].
Vascular endothelial growth factor (VEGF), basic-fibro-
blast growth factor (b-FGF), and endothelial nitric oxide
synthase (eNOS; type III nitric oxide enzyme) have been
identified as positive regulators of angiogenesis [8]. They
are strongly expressed during embryonic and fetal devel-
opment, especially in the first trimester [1,6,10,12-14].
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VEGF, one of the first angiogenic factors identified, is
widely believed to be the most important regulator of
both normal and pathological angiogenesis [15]. It plays
an essential role in the formation of new blood vessels
[8,12]. In pregnancy, VEGF participates in the prolifera-
tion, migration, and metabolic activity of trophoblasts
[3,4,6,12]. It is expressed by human villous and extravil-
lous trophoblasts, and conclusive evidence indicates that
it regulates trophoblast function by stimulating release of
nitric oxide [4]. b-FGF acts as a modulator of tissue dif-
ferentiation and placental angiogenesis [3,6,10,13], and
eNOS has an important role in the regulation of placental
blood flow [14].
In this study, we investigated the relationship between
placental angiogenesis and the expression of VEGF-A, b-
FGF, and eNOS in normal-term pregnancy and IUGR
placentas.
Methods
Patients
A total of 110 placental tissues from uncomplicated and
IUGR pregnancies were included in the study. These were
collected from the Zonguldak Karaelmas University Hos-
pital, Department of Gynecology and Obstetrics. Placen-
tas from twin pregnancies, infants with congenital
anomalies, fetal aneuploidy, those with proven intrauter-
ine infections, and those from pregnancies with maternal
complications such as chronic hypertension, diabetes
mellitus, or autoimmune diseases were excluded from the
study.
Tissue samples
Placental tissues were divided in two study groups. The
control group consisted of placental tissues collected
from 55 women with uncomplicated pregnancies who
delivered in the third trimester. The IUGR group con-
tained tissues collected from 55 women in whom IUGR
was defined on the basis of an estimated fetal weight of
less than the tenth percentile for gestational age, reduced
amniotic fluid volume, and Doppler ultrasound of the
umbilical artery demonstrating absent end diastolic flow
velocity [16]. The diagnosis of IUGR was established by
serial obstetric ultrasonographic (ultrasound equipment:
GE Logiq 7®, Penta Electronics, Ankara, Turkey) examina-
t i o n  o f  f e t a l  m e a s u r e m e n t s  s u c h  a s  w e i g h t ,  b i p a r i e t a l
diameter, head circumference, femur length, and abdomi-
nal circumference. The placentas were weighed after
removal of the cords and membranes. Multiple random
samples were taken from each placenta, including one
from the cord and one from the membrane roll.
Immunohistochemistry
Expression of VEGF-A, b-FGF, and eNOS was analyzed
in 110 placental villous tissues. Samples (1.5 × 1.5 × 1 cm
in diameter) taken from the maternal surface of each pla-
centa; infarct areas were excluded from the study. All tis-
sues were fixed in formalin, embedded in paraffin, and
cut into 5-μm-thick sections, which were collected on
slides coated with poly-L-lysine. After the paraffin was
removed, the sections were rehydrated. Immunostaining
was performed by the streptavidin-biotin-peroxidase
method. Endogenous peroxidase activity was blocked
using 3% hydrogen peroxide. Antigen retrieval was car-
ried out in a microwave oven for 15 minutes in 10 nM cit-
rate buffer (pH 6.0) for VEGF-A and eNOS. No antigen
retrieval was used for b-FGF antibody. The sections were
incubated at room temperature for one hour with RB-
222-P rabbit polyclonal antibodies reactive with VEGF-A
(a subgroup of VEGF) (1:100; NeoMarkers, Fremont, CA,
USA), sc-79 mouse monoclonal antibodies reactive with
FGF-2 (147) (1:50; Santa Cruz Biotechnology, Inc., Santa
Cruz, California), and rabbit polyclonal antibodies reac-
tive with eNOS (NeoMarkers, Fremont, CA, USA). After
washing in phosphate-buffered saline with Tween-20, the
Table 1: Clinicopathological data and statistical comparison between IUGR and normal pregnancy
Clinical data Normal pregnancy
(n: 55)
IUGR
(n: 55)
P value
Maternal age (year) 25.9 ± 4.1 27.0 ± 4.5 0.191
Gestational age (week) 38.9 ± 5.9 36.3 ± 22.9 0.000
Apgar score (mean) 1. minute 8.7 ± 1.2 5.9 ± 3.6 0.000
Apgar score (mean) 5. minute 9.7 ± 0.6 7.0 ± 2.9 0.000
Birth weight (g) 3041.5 ± 453.3 2023.9 ± 674.8 0.000
Placental weight (g) 508.9 ± 104.6 404.6 ± 161.2 0.000
Placental diameter (cm) 15.9 ± 1.5 13.6 ± 2.7 0.000
Umbilical cord length (cm) 29.2 ± 4.3 25.6 ± 6.3 0.000
Data were given as mean ± SD
*P: Statistical comparison of normal and IUGR placental tissuesBarut et al. Diagnostic Pathology 2010, 5:24
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tissues were incubated with a biotin-conjugated second-
ary antibody and then with a biotin-streptavidin complex
for 30 min at room temperature. Reactions were visual-
ized with 3,3-diaminobenzidine tetrahydrochloride
(DAB). Sections were counterstained with hematoxylin,
rinsed, and mounted.
Evaluation of immunohistochemical staining
The intensity and localization of the staining reaction in
chorionic villous stromal cells, vascular smooth muscle
cells, villous vascular endothelial cells, cytotrophoblasts,
syncytiotrophoblasts, and extravillous trophoblasts was
evaluated by two investigators blind to the purpose of the
study. Immunoreactivity for antibodies was scored using
a semi-quantitative scale for intensity of staining: 0 nega-
tive, no staining; 1+ weak positive; 2+ moderately posi-
tive; 3+ strongly positive.
Statistical analysis
Statistical analysis was carried out using SPSS for Win-
dows (version 13.0, Chicago, IL, USA). Continuous vari-
ables are presented as mean ± SD. Categorical variables
are presented in percentages. Student's t-test and Mann-
Whitney U-test were used to compare groups for clinical
and immunohistochemical findings. P-values < 0.001
were considered statistically significant.
Results
Clinical and pathological data, including maternal, neo-
natal, and placental parameters are shown in Table 1. The
mean gestational age of the normal pregnancies and
those complicated by IUGR was 38.9 ± 5.9 weeks and 36.3
± 22.9 weeks, respectively. Birth weight, placental weight,
placental diameter, umbilical cord length, and APGAR
s c o r e s  w e r e  d e m o n s t r a t e d  t o  b e  s i g n i f i c a n t l y  d i f f e r e n t
between the two groups.
The clinical and morphological features commonly
associated with IUGR observed in 55 placentas are
recorded in Table 2. A histological comparison of normal
term pregnancy and IUGR placental tissues showed
widespread infarct areas and increased syncytial knots or
Tenney-Parker changes in the IUGR placentas (Fig. 1A,
B).
Staining after incubation with primary antibodies reac-
tive with VEGF-A, b-FGF, and eNOS was observed in the
cytoplasm of placental cells from normal term pregnancy
and IUGR tissues. Expression of VEGF-A, b-FGF, and
eNOS in placental villous tissues was semi-quantified
(Tables 3, 4 and 5). A statistically significant (p < 0.001)
increase in the expression of VEGF-A, b-FGF, and eNOS
in IUGR placentas was observed in cytotrophoblast, syn-
cytiotrophoblast, extravillous trophoblast, vascular
smooth muscle, and villous stromal and endothelial cells
compared with normal term pregnancy placentas.
In normal term pregnancy placentas, staining was weak
and located predominantly in the cytotrophoblasts and
syncytiotrophoblasts (Fig. 2A, 3A, 4A). In IUGR placen-
tas, strong staining was obtained with VEGF-A (Fig. 2B),
b-FGF (Fig. 3B), and eNOS (Fig. 4B) primary antibodies.
Table 2: The evaluation of clinical and placental datas of 55 pregnancies complicated with IUGR
Clinical data n (%) Placental data n (%)
Cesarean section rate 46 (83.6) Umbilical cord knots 8 (14.5)
Fetal distress 9 (16.4) Single umbilical artery 1 (1.8)
Premature rupture of the 
membranes
2 (3.6) Placental infarction 51 (92.7)
Preterm birth 4 (7.3) Placental calcification 31 (56.4)
Prematurity 1 (1.8) Placental chorangiosis 3 (5.5)
Neonatal intensive care need 13 (23.6) Chorioamnionitis 4 (7.3)
Neonatal hypoglycemia 1 (1.8) Accessory lobe 1 (1.8)
Intrauterine fetal death 3 (5.5)
Figure 1 Histopathologic appearances of placental tissues A; 
Normal placental tissue B; Increased syncytial knots and villous 
vascular structures in IUGR placental tissue (H&E A; B; ×200).Barut et al. Diagnostic Pathology 2010, 5:24
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Discussion
IUGR is an important cause of perinatal morbidity and
mortality. In developed countries, the incidence of IUGR
is 3%, whereas in developing countries, it reaches 15-20%.
It is one of the most commonly recognized abnormalities
of the fetal condition and is a compounding factor in 26%
or more of stillbirths [1,4,5]. It may also have long-term
health implications for adults [17]. For these reasons, the
accurate prediction, diagnosis, and appropriate manage-
ment of pregnancies complicated with IUGR are impor-
tant. In accordance with the clinical definition of IUGR,
we observed significantly reduced fetal birth weight,
amniotic fluid, and placental size and weight in our IUGR
group.
The placenta, which normally has a rich vasculature,
plays an important role in the development of IUGR. The
most common cause of IUGR is placenta ischemia in
which insufficient placental function results from deteri-
orated uteroplacental perfusion [3,5,7,18]. The clinical
features of ischemic placental disease are revealed
throughout the second half of pregnancy, but the
pathophysiological processes initiating the disease origi-
nate in the first half [17]. The process of promoting the
development of neovessels may be activated by chemo-
cytokines in some pathological situations such as isch-
emia [12]. Structural evidence suggests that placental
oxygenation is important in controlling fetoplacental
angiogenesis and hence, villous differentiation [9]. Insuf-
Table 4: b-FGF expression in placental villous tissues
Normal pregnancy
(n: 55)
IUGR
(n: 55)
Statistical 
comparison
P value
Score 0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
P*
CVSC - 55 (100) - - - - - 55 (100) <0.001
VSMC 43 (78.2) 12 (21.8) - - - - - 55 (100) <0.001
VVEC 43 (78.2) 12 (21.8) - - - - - 55 (100) <0.001
ST - 55 (100) - - - - - 55 (100) <0.001
CT - 55 (100) - - - - - 55 (100) <0.001
EVT 55 (100) - - - - - - 55 (100) <0.001
IUGR: Intrauterine growth restricted; CVSC: Chorionic villous stromal cells; VSMC: Vascular smooth muscle cells; VVEC: Villous vascular endothelial 
cells; ST: Syncytiotrophoblasts; CT; Cytotrophoblasts; EVT: Extravillous trophoblasts [Staining intensity of FGF-b were scored as follows: 0 
(negative), weak (1+), moderate (2+), and strong (3+)] *P: Statistical comparison of normal and IUGR placental tissues
Table 3: Localization and immunostaining intensity of VEGF expression in placental villous tissues
Normal pregnancy
(n: 55)
IUGR
(n: 55)
Statistical 
comparison
P value
Score 0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
P*
CVSC - 55 (100) - - - - - 55 (100) <0.001
VSMC - 55 (100) - - - - - 55 (100) <0.001
VVEC - 55 (100) - - - - - 55 (100) <0.001
ST - 55 (100) - - - - - 55 (100) <0.001
CT - 55 (100) - - - - - 55 (100) <0.001
EVT 55 (100) - - - - - 55 (100) <0.001
IUGR: Intrauterine growth restricted; CVSC: Chorionic villous stromal cells; VSMC: Vascular smooth muscle cells; VVEC: Villous vascular endothelial 
cells; ST: Syncytiotrophoblasts; CT; Cytotrophoblasts; EVT: Extravillous trophoblasts [Staining intensity of VEGF were scored as follows: 0 
(negative), weak (1+), moderate (2+), and strong (3+)] *P: Statistical comparison of normal and IUGR placental tissuesBarut et al. Diagnostic Pathology 2010, 5:24
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ficient uteroplacental perfusion leading to abnormal
angiogenesis may result in the pathophysiology of IUGR
[3,4].
Changes appearing during placental development can
be used as early markers of pathologies that may occur
later in pregnancy. Placental ischemia is one such pathol-
ogy, and it can be investigated in relation to various
angiogenic mediators [17]. A hypoxic stimulus may lead
to an excessive proliferation of villous capillaries and con-
nective tissue via growth factors such as VEGF and FGF
[19]. Abnormal vasculogenesis, angiogenesis, and pseu-
dovasculogenesis is correlated with the impaired placen-
tal and fetal development seen in complicated
pregnancies such as IUGR [3] Angiogenesis may be regu-
lated by oxygen status and by the production of angio-
genic growth factors and their natural receptors and
antagonists by vascular endothelial cells, pericytes, and
trophoblasts. The resulting changes in fetal vasculature
are associated with altered patterns of villous growth
[18]. The results from our study support the literature
reporting that an alteration in placental development
accompanying deteriorated angiogenesis occurs in IUGR
[4,11,17,18]. Contrary to our findings, Lyall et al. [20]
demonstrated a reduction in villous placenta VEGF
Figure 2 VEGF expression in placental tissues, A; Weak VEGF ex-
pression in cytotrophoblasts and syncytiotrophoblasts in normal 
pregnancy placenta, B; Strong immune reaction with VEGF in 
IUGR placental tissue (B-SA peroxidase, DAB, A; B; ×200).
Table 5: Localization and immunostaining intensity of eNOS expression in placental villous tissues
Normal pregnancy
(n: 55)
IUGR
(n: 55)
Statistical 
comparison
P value
Score 0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
0
n (%)
1+
n (%)
2+
n (%)
3+
n (%)
P*
CVSC - 55 (100) - - - - 10 (18.2) 45 (81.8) <0.001
VSMC 48 (87.3) 7 (12.7) - - - - 14 (25.5) 41 (74.5) <0.001
VVEC 48 (87.3) 7 (12.7) - - - - 14 (25.5) 41 (74.5) <0.001
ST - 55 (100) - - - - - 55 (100) <0.001
CT - 55 (100) - - - - - 55 (100) <0.001
EVT 55 (100) - - - - - - 55 (100) <0.001
IUGR: Intrauterine growth restricted; CVSC: Chorionic villous stromal cells; VSMC: Vascular smooth muscle cells; VVEC: Villous vascular endothelial 
cells; ST: Syncytiotrophoblasts; CT; Cytotrophoblasts; EVT: Extravillous trophoblasts [Staining intensity of eNOS were scored as follows: 0 
(negative), weak (1+), moderate (2+), and strong (3+)] *P: Statistical comparison of normal and IUGR placental tissues
Figure 4 eNOS expression in placental tissues, A; Weak eNOS ex-
pression in normal pregnancy placenta, B; Strong immune reac-
tion with eNOS in IUGR placenta (B-SA peroxidase, DAB, A; B; 
×200). The English in this document has been checked by at least two 
professional editors, both native speakers of English. For a certificate, 
please see: http://www.textcheck.com/certificate/muDdOzBarut et al. Diagnostic Pathology 2010, 5:24
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expression in placental villous tissue from pregnancies
complicated by IUGR and preeclampsia.
It is thought that the angiogenic factors VEGF, b-FGF,
and eNOS have important roles in villous proliferation,
trophoblast function, and angiogenesis as characterized
by the formation of new vascular structures in the villous
stroma [14]. VEGF is thought to exert a dual role in the
placenta, acting on both angiogenesis and trophoblast
function during placental development. The roles of
VEGF, b-FGF and eNOS in placental angiogenesis may be
altered in conditions such as IUGR [4,14]. The increased
expression of VEGF-A, b-FGF, and eNOS that we have
found in IUGR placentas may promote increased
endothelial cell proliferation and migration and patholog-
ical angiogenesis [17]. It is likely that normal placental
angiogenesis depends on the regulation of vascular devel-
opment by a complex relationships among these factors
and that they play an important role in the development
of IUGR.
Conclusion
It is necessary to explain the regulatory mechanism of
placental vascular development in order to elucidate the
pathogenesis of IUGR and the associated placental vascu-
lar insufficiency. The observed, increased expression of
VEGF-A, b-FGF, and eNOS suggests that abnormal
angiogenic activity, caused by insufficient uteroplacental
perfusion, results in the pathophysiology of IUGR.
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